Merck Asks Justices To Block Fosamax Failure-To-Warn Suits

By Emily Field · March 13, 2025, 8:20 PM EDT

Merck has asked the U.S. Supreme Court to review a Third Circuit ruling that allowed more than 1,000 state-law failure-to-warn claims over its osteoporosis drug Fosamax, arguing that the U.S. Food...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Petition

Case Information

Case Title

Merck Sharp & Dohme Corporation, Petitioner v. Doris Albrecht, et al.

Case Number

Court

Supreme Court

Nature of Suit

4365 Personal Injury-Product Liability

Date Filed

March 12, 2025

Recent Articles By Emily

March 14, 2025
Antigua Clinic Accused Of Lying About 'Miracle' Cancer Cure
March 11, 2025
'Paucity' Of Proof Thwarts NC State Law Claims In Gardasil MDL
January 07, 2025
Alcohol Warnings Unlikely To Bring Same Fate Tobacco Faced
December 10, 2024
Ohio Justices Reject Opioid Nuisance Claims In $650M Appeal
November 05, 2024
Target Inks Individual Deals Over 'Non-Drowsy' Flu Medicine
October 10, 2024
Animal Medication Co. Sued Over Dog Arthritis Treatment Risks
August 26, 2024
Rival Can't Avoid Drugmaker's False Ad Claim Over Pain Med
August 21, 2024
Spine Implant Caused Patient's TB, Suit Says
July 23, 2024
Meet The Lead Ozempic Lawyers
June 24, 2024
Ark. AG Sues Pharmacy Benefit Managers Over Opioids